Seminars in Oncology
Volume 32, Issue 1 , Pages 24-34 , February 2005

Colorectal cancer prevention: Is an ounce of prevention worth a pound of cure?

  • Sharlene Gill

      Affiliations

    • Division of Oncology, Mayo Clinic and Mayo College of Medicine, Rochester, MN.
    • ,
  • Frank A. Sinicrope

      Affiliations

    • Division of Oncology, Mayo Clinic and Mayo College of Medicine, Rochester, MN.
    • Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo College of Medicine, Rochester, MN.
    • Corresponding Author InformationAddress reprint requests to Frank A. Sinicrope, MD, FACP, Divisions of Oncology and Gastroenterology and Hepatology, Mayo Clinic and Mayo College of Medicine, 200 First Street SW, Rochester, MN 55905.

References 

  1. Tiwari T , Murray T . Cancer statistics, 2004 . CA Cancer J Clin . 2004;54:8–29
  2. NCI-C . National Cancer Institute of Canada, Canadian Cancer Statistics . 2003; www.cancer.ca
  3. Vogelstein B , Fearon ER , Hamilton SR , et al.   Genetic alterations during colorectal-tumor development . N Engl J Med . 1988;319:525–532
  4. Thibodeau SN , Bren G , Schaid D . Microsatellite instability in cancer of the proximal colon . Science . 1993;260:816–819
  5. Gryfe R , Kim H , Hsieh ET , et al.   Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer . N Engl J Med . 2000;342:69–77
  6. Lynch HT , Smyrk T , Lynch J . An update of HNPCC (Lynch syndrome) . Cancer Genet Cytogenet . 1997;93:84–99
  7. Aaltonen LA , Salovaara R , Kristo P , et al.   Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease . N Engl J Med . 1998;338:1481–1487
  8. Williams AR , Balasooriya BA , Day DW . Polyps and cancer of the large bowel (A necropsy study in Liverpool) . Gut . 1982;23:835–842
  9. Winawer SJ , Zauber AG , Ho MN , et al.  The National Polyp Study Workgroup   Prevention of colorectal cancer by colonoscopic polypectomy . N Engl J Med . 1993;329:1977–1981
  10. Viner JL , Umar A , Hawk ET . Chemoprevention of colorectal cancer (Problems, progress, and prospects) . Gastroenterol Clin North Am . 2002;31:971–999
  11. Burt RW , Bishop DT , Cannon LA , et al.   Dominant inheritance of adenomatous colonic polyps and colorectal cancer . N Engl J Med . 1985;312:1540–1544
  12. Waddell WR , Ganser GF , Cerise EJ , et al.   Sulindac for polyposis of the colon . Am J Surg . 1989;157:175–179
  13. Thun MJ , Namboodiri MM , Heath CW . Aspirin use and reduced risk of fatal colon cancer . N Engl J Med . 1991;325:1593–1596
  14. Giovannucci E , Rimm EB , Stampfer MJ , et al.   Aspirin use and the risk for colorectal cancer and adenoma in male health professionals . Ann Intern Med . 1994;121:241–246
  15. Giovannucci E , Egan KM , Hunter DJ , et al.   Aspirin and the risk of colorectal cancer in women . N Engl J Med . 1995;333:609–614
  16. Sturmer T , Glynn RJ , Lee IM , et al.   Aspirin use and colorectal cancer (Post-trial follow-up data from the Physicians’ Health Study) . Ann Intern Med . 1998;128:713–720
  17. Smalley W , Ray WA , Daugherty J , et al.   Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer (A population-based study) . Arch Intern Med . 1999;159:161–166
  18. Chan AT , Giovannucci EL , Schernhammer ES , et al.   A prospective study of aspirin use and the risk for colorectal adenoma . Ann Intern Med . 2004;140:157–166
  19. Herschman HR , Xie W , Reddy S . Inflammation, reproduction, cancer and all that…. The regulation and role of the inducible prostaglandin synthase . Bioessays . 1995;17:1031–1037
  20. Eberhart CE , Coffey RJ , Radhika A , et al.   Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas . Gastroenterology . 1994;107:1183–1188
  21. Sinicrope FA , Lemoine M , Xi L , et al.   Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers . Gastroenterology . 1999;117:350–358
  22. FitzGerald GA , Patrono C . The coxibs, selective inhibitors of cyclooxygenase-2 . N Engl J Med . 2001;345:433–442
  23. Oshima M , Dinchuk JE , Kargman SL , et al.   Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2) . Cell . 1996;87:803–809
  24. Kawamori T , Rao CV , Seibert K , et al.   Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis . Cancer Res . 1998;58:409–412
  25. Jacoby RF , Marshall DJ , Newton MA , et al.   Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam . Cancer Res . 1996;56:710–714
  26. Mahmoud NN , Boolbol SK , Dannenberg AJ , et al.   The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis . Carcinogenesis . 1998;19:87–91
  27. Oshima M , Murai N , Kargman S , et al.   Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor . Cancer Res . 2001;61:1733–1740
  28. Gupta RA , DuBois RN . Aspirin, NSAIDS, and colon cancer prevention (mechanisms?) . Gastroenterology . 1998;114:1095–1098
  29. Sun Y , Tang XM , Half E , et al.   Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells . Cancer Res . 2002;62:6323–6328
  30. Bedi A , Pasricha PJ , Akhtar AJ , et al.   Inhibition of apoptosis during development of colorectal cancer . Cancer Res . 1995;55:1811–1816
  31. Yamazaki R , Kusunoki N , Matsuzaki T , et al.   Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells . FEBS Lett . 2002;531:278–284
  32. Grosch S , Tegeder I , Niederberger E , et al.   COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib . FASEB J . 2001;15:2742–2744
  33. Shiff SJ , Qiao L , Tsai LL , et al.   Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells . J Clin Invest . 1995;96:491–503
  34. Piazza GA , Rahm AL , Krutzsch M , et al.   Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis . Cancer Res . 1995;55:3110–3116
  35. Tang X , Sun YJ , Half E , et al.   Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells . Cancer Res . 2002;62:4903–4908
  36. Huang Y , He Q , Hillman MJ , et al.   Sulindac sulfide-induced apoptosis involves death receptor 5 and the caspase 8-dependent pathway in human colon and prostate cancer cells . Cancer Res . 2001;61:6918–6924
  37. Zhang L , Yu J , Park BH , et al.   Role of BAX in the apoptotic response to anticancer agents . Science . 2000;290:989–992
  38. Elder DJ , Halton DE , Hague A , et al.   Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug (Independence from COX-2 protein expression) . Clin Cancer Res . 1997;3:1679–1683
  39. Sheng GG , Shao J , Sheng H , et al.   A selective cyclooxygenase 2 inhibitor suppresses the growth of H-ras-transformed rat intestinal epithelial cells . Gastroenterology . 1997;113:1883–1891
  40. Samaha HS , Kelloff GJ , Steele V , et al.   Modulation of apoptosis by sulindac, curcumin, phenylethyl-3- methylcaffeate, and 6-phenylhexyl isothiocyanate (Apoptotic index as a biomarker in colon cancer chemoprevention and promotion) . Cancer Res . 1997;57:1301–1305
  41. Morin PJ , Vogelstein B , Kinzler KW . Apoptosis and APC in colorectal tumorigenesis . Proc Natl Acad Sci U S A . 1996;93:7950–7954
  42. Keller JJ , Offerhaus GJ , Polak M , et al.   Rectal epithelial apoptosis in familial adenomatous polyposis patients treated with sulindac . Gut . 1999;45:822–828
  43. Keller JJ , Offerhaus GJ , Hylind LM , et al.   Rectal epithelial apoptosis does not predict response to sulindac treatment or polyp development in presymptomatic familial adenomatous polyposis patients . Cancer Epidemiol Biomarkers Prev . 2002;11:670–671
  44. Sinicrope FA , Half E , Morris JS , et al.   Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis (FAP) patients . Cancer Epidemiol Biomarkers Prev . 2004;3:1–8
  45. Tsujii M , Kawano S , DuBois RN . Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential . Proc Natl Acad Sci U S A . 1997;94:3336–3340
  46. Masferrer JL , Leahy KM , Koki AT , et al.   Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors . Cancer Res . 2000;60:1306–1311
  47. Tsujii M , Kawano S , Tsuji S , et al.   Cyclooxygenase regulates angiogenesis induced by colon cancer cells . Cell . 1998;93:705–716
  48. Hanif R , Pittas A , Feng Y , et al.   Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway . Biochem Pharmacol . 1996;52:237–245
  49. Molina MA , Sitja-Arnau M , Lemoine MG , et al.   Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines (Growth inhibition by nonsteroidal anti-inflammatory drugs) . Cancer Res . 1999;59:4356–4362
  50. Piazza GA , Alberts DS , Hixson LJ , et al.   Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels . Cancer Res . 1997;57:2909–2915
  51. Alberts DS , Hixson L , Ahnen D , et al.   Do NSAIDs exert their colon cancer chemoprevention activities through the inhibition of mucosal prostaglandin synthetase? . J Cell Biochem . 1995;22(suppl):18–23
  52. Williams CS , Watson AJ , Sheng H , et al.   Celecoxib prevents tumor growth in vivo without toxicity to normal gut (Lack of correlation between in vitro and in vivo models) . Cancer Res . 2000;60:6045–6051
  53. Kopp E , Ghosh S . Inhibition of NF-kappa B by sodium salicylate and aspirin . Science . 1994;265:956–959
  54. Lehmann JM , Lenhard JM , Oliver BB , et al.   Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs . J Biol Chem . 1997;272:3406–3410
  55. He TC , Chan TA , Vogelstein B , et al.   PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs . Cell . 1999;99:335–345
  56. Giardiello FM , Hamilton SR , Krush AJ , et al.   Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis . N Engl J Med . 1993;328:1313–1316
  57. Steinbach G , Lynch PM , Phillips RK , et al.   The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis . N Engl J Med . 2000;342:1946–1952
  58. Giardiello FM , Yang VW , Hylind LM , et al.   Primary chemoprevention of familial adenomatous polyposis with sulindac . N Engl J Med . 2002;346:1054–1059
  59. Sandler RS , Halabi S , Baron JA , et al.   A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer . N Engl J Med . 2003;348:883–890
  60. Baron JA , Cole BF , Sandler RS , et al.   A randomized trial of aspirin to prevent colorectal adenomas . N Engl J Med . 2003;348:891–899
  61. Sample D , Wargovich M , Fischer SM , et al.   A dose-finding study of aspirin for chemoprevention utilizing rectal mucosal prostaglandin E(2) levels as a biomarker . Cancer Epidemiol Biomarkers Prev . 2002;11:275–279
  62. Benamouzig R , Deyra J , Martin A , et al.   Daily soluble aspirin and prevention of colorectal adenoma recurrence (One-year results of the APACC trial) . Gastroenterology . 2003;125:328–336
  63. Ladabaum U , Chopra CL , Huang G , et al.   Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysis . Ann Intern Med . 2001;135:769–781
  64. Suleiman S , Rex DK , Sonnenberg A . Chemoprevention of colorectal cancer by aspirin (A cost-effectiveness analysis) . Gastroenterology . 2002;122:78–84
  65. Hayden M , Pignone M , Phillips C , et al.   Aspirin for the primary prevention of cardiovascular events: A summary of the evidence for the U.S. Preventive Services Task Force . Ann Intern Med . 2002;136:161–172
  66. Bensen WG , Zhao SZ , Burke TA , et al.   Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo . J Rheumatol . 2002;27:1876–1883
  67. Silverstein FE , Faich G , Goldstein JL , et al.   Gastrointestinal toxicity with celecoxib vs nonsteroidal anti- inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study . JAMA . 2000;284:1247–1255
  68. Goldstein JL , Silverstein FE , Agrawal NM , et al.   Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor . Am J Gastroenterol . 2000;95:1681–1690
  69. Chan FK , Hung LC , Suen BY , et al.   Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis . N Engl J Med . 2002;347:2104–2110
  70. Ray WA , Stein CM , Daugherty JR , et al.   COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease . Lancet . 2002;360:1071–1073
  71. Mukherjee D , Nissen SE , Topol EJ . Risk of cardiovascular events associated with selective COX-2 inhibitors . JAMA . 2001;286:954–959
  72. Newton NE , Abdel-Monem MM . Inhibitors of polyamine biosynthesis. 4. Effects of alpha-methyl-(+/−)-ornithine and methylglyoxal bis(guanylhydrazone) on growth and polyamine content of L1210 leukemic cells of mice . J Med Chem . 1977;20:249–253
  73. Pohjanpelto P , Holtta E , Janne OA , et al.   Amplification of ornithine decarboxylase gene in response to polyamine deprivation in Chinese hamster ovary cells . J Biol Chem . 1985;260:8532–8537
  74. Luk GD , Baylin SB . Ornithine decarboxylase as a biologic marker in familial colonic polyposis . N Engl J Med . 1984;311:80–83
  75. Rozhin J , Wilson PS , Bull AW , et al.   Ornithine decarboxylase activity in the rat and human colon . Cancer Res . 1984;44:3226–3230
  76. Hixson LJ , Garewal HS , McGee DL , et al.   Ornithine decarboxylase and polyamines in colorectal neoplasia and mucosa . Cancer Epidemiol Biomarkers Prev . 1993;2:369–374
  77. Bello-Fernandez C , Packham G , Cleveland JL . The ornithine decarboxylase gene is a transcriptional target of c-Myc . Proc Natl Acad Sci U S A . 1993;90:7804–7808
  78. Augenlicht LH , Wadler S , Corner G , et al.   Low-level c-myc amplification in human colonic carcinoma cell lines and tumors (A frequent, p53-independent mutation associated with improved outcome in a randomized multi-institutional trial) . Cancer Res . 1997;57:1769–1775
  79. He TC , Sparks AB , Rago C , et al.   Identification of c-MYC as a target of the APC pathway . Science . 1998;281:1509–1512
  80. Erdman SH , Ignatenko NA , Powell MB , et al.   APC-dependent changes in expression of genes influencing polyamine metabolism, and consequences for gastrointestinal carcinogenesis, in the Min mouse . Carcinogenesis . 1999;20:1709–1713
  81. Meyskens FL , Gerner EW . Development of difluoromethylornithine (DFMO) as a chemoprevention agent . Clin Cancer Res . 1999;5:945–951
  82. Wang W , Liu LQ , Higuchi CM . Mucosal polyamine measurements and colorectal cancer risk . J Cell Biochem . 1996;63:252–257
  83. Meyskens FL , Gerner EW , Emerson S , et al.   Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention . J Natl Cancer Inst . 1998;90:1212–1218
  84. Jacoby RF , Cole CE , Tutsch K , et al.   Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos . Cancer Res . 2000;60:1864–1870
  85. Li H , Schut HA , Conran P , et al.   Prevention by aspirin and its combination with alpha-difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colon . Carcinogenesis . 1999;20:425–430
  86. Martinez ME , O’Brien TG , Fultz KE , et al.   Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene . Proc Natl Acad Sci U S A . 2003;100:7859–7864
  87. Deschner EE , Cohen BI , Raicht RF . Acute and chronic effect of dietary cholic acid on colonic epithelial cell proliferation . Digestion . 1981;21:290–296
  88. Hori T , Matsumoto K , Sakaitani Y , et al.   Effect of dietary deoxycholic acid and cholesterol on fecal steroid concentration and its impact on the colonic crypt cell proliferation in azoxymethane-treated rats . Cancer Lett . 1998;124:79–84
  89. Cohen BI , Raicht RF , Deschner EE , et al.   Effect of cholic acid feeding on N-methyl-N-nitrosourea-induced colon tumors and cell kinetics in rats . J Natl Cancer Inst . 1980;64:573–578
  90. Stadler J , Yeung KS , Furrer R , et al.   Proliferative activity of rectal mucosa and soluble fecal bile acids in patients with normal colons and in patients with colonic polyps or cancer . Cancer Lett . 1988;38:315–320
  91. Narisawa T , Fukaura Y , Terada K , et al.   Inhibitory effects of ursodeoxycholic acid on N-methylnitrosourea-induced colon carcinogenesis and colonic mucosal telomerase activity in F344 rats . J Exp Clin Cancer Res . 1999;18:259–266
  92. Earnest DL , Holubec H , Wali RK , et al.   Chemoprevention of azoxymethane-induced colonic carcinogenesis by supplemental dietary ursodeoxycholic acid . Cancer Res . 1994;54:5071–5074
  93. Pardi DS , Loftus EV , Kremers WK , et al.   Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis . Gastroenterology . 2003;124:889–893
  94. Alberts DS , Martinez ME , Roe D , et al.   Proving the bile acid hypothesis for colon carcinogenesis (Mature results from a phase III chemoprevention trial of ursodeoxycholic acid versus placebo to prevent colorectal adenoma recurrence) . Proc Am Soc Clin Oncol . 2003;22:91; (abstr 363)
  95. Pedersen TR , Berg K , Cook TJ , et al.   Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study . Arch Intern Med . 1996;156:2085–2092
  96. Sacks FM , Pfeffer MA , Moye LA , et al.   The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators . N Engl J Med . 1996;335:1001–1009
  97. Narisawa T , Fukaura Y , Terada K , et al.   Prevention of 1,2-dimethylhydrazine-induced colon tumorigenesis by HMG-CoA reductase inhibitors, pravastatin and simvastatin, in ICR mice . Carcinogenesis . 1994;15:2045–2048
  98. Agarwal B , Rao CV , Bhendwal S , et al.   Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac . Gastroenterology . 1999;117:838–847
  99. Calle EE , Miracle-McMahill HL , Thun MJ , et al.   Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women . J Natl Cancer Inst . 1995;87:517–523
  100. Grodstein F , Martinez ME , Platz EA , et al.   Postmenopausal hormone use and risk for colorectal cancer and adenoma . Ann Intern Med . 1998;128:705–712
  101. Campagnoli C , Biglia N , Altare F , et al.   Differential effects of oral conjugated estrogens and transdermal estradiol on insulin-like growth factor 1, growth hormone and sex hormone binding globulin serum levels . Gynecol Endocrinol . 1993;7:251–258
  102. McMichael AJ , Potter JD . Reproduction, endogenous and exogenous sex hormones, and colon cancer (A review and hypothesis) . J Natl Cancer Inst . 1980;65:1201–1207
  103. Rossouw JE , Anderson GL , Prentice RL , et al.   Risks and benefits of estrogen plus progestin in healthy postmenopausal women (Principal results From the Women’s Health Initiative randomized controlled trial) . JAMA . 2002;288:321–333
  104. Hyman J , Baron JA , Dain BJ , et al.   Dietary and supplemental calcium and the recurrence of colorectal adenomas . Cancer Epidemiol Biomarkers Prev . 1998;7:291–295
  105. Martinez ME , Willett WC . Calcium, vitamin D, and colorectal cancer (A review of the epidemiologic evidence) . Cancer Epidemiol Biomarkers Prev . 1998;7:163–168
  106. Baron JA , Beach M , Mandel JS , et al.  Calcium Polyp Prevention Study Group   Calcium supplements for the prevention of colorectal adenomas . N Engl J Med . 1999;340:101–107
  107. Grau MV , Baron JA , Sandler RS , et al.   Vitamin D, calcium supplementation, and colorectal adenomas (Results of a randomized trial) . J Natl Cancer Inst . 2003;95:1765–1771
  108. Lamprecht SA , Lipkin M . Chemoprevention of colon cancer by calcium, vitamin D and folate (molecular mechanisms) . Nat Rev Cancer . 2003;3:601–614
  109. Giovannucci E , Stampfer MJ , Colditz GA , et al.   Multivitamin use, folate, and colon cancer in women in the Nurses’ Health Study . Ann Intern Med . 1998;129:517–524
  110. Fuchs CS , Willett WC , Colditz GA , et al.   The influence of folate and multivitamin use on the familial risk of colon cancer in women . Cancer Epidemiol Biomarkers Prev . 2002;11:227–234
  111. Baron JA , Sandler RS , Haile RW , et al.   Folate intake, alcohol consumption, cigarette smoking, and risk of colorectal adenomas . J Natl Cancer Inst . 1998;90:57–62
  112. Alberts DS , Martinez ME , Roe DJ , et al.   Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians’ Network . N Engl J Med . 2000;342:1156–1162
  113. Martinez ME , Henning SM , Alberts DS . Folate and colorectal neoplasia (relation between plasma and dietary markers of folate and adenoma recurrence) . Am J Clin Nutr . 2004;79:691–697
  114. Vinceti M , Rovesti S , Bergomi M , et al.   The epidemiology of selenium and human cancer . Tumori . 2000;86:105–118
  115. Feng Y , Finley JW , Davis CD , et al.   Dietary selenium reduces the formation of aberrant crypts in rats administered 3,2′-dimethyl-4-aminobiphenyl . Toxicol Appl Pharmacol . 1999;157:36–42
  116. Rao CV , Cooma I , Rodriguez JG , et al.   Chemoprevention of familial adenomatous polyposis development in the APC(min) mouse model by 1,4-phenylene bis(methylene)selenocyanate . Carcinogenesis . 2000;21:617–621
  117. Clark LC , Combs GF , Turnbull BW , et al.  Nutritional Prevention of Cancer Study Group   Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial . JAMA . 1996;276:1957–1963
  118. Umar A , Viner JL , Hawk ET . The future of colon cancer prevention . Ann N Y Acad Sci . 2001;952:88–108
  119. Humar B , D’Orazio D , Albrecht C , et al.   Expression of putative anticancer targets in familial adenomatous polyposis and its association with the APC mutation status . Int J Oncol . 2001;19:1179–1186
  120. Dolara P , Caderni G , Lancioni L , et al.   Aberrant crypt foci in human colon carcinogenesis . Cancer Detect Prev . 1997;21:135–140
  121. Pereira MA , Barnes LH , Rassman VL , et al.   Use of azoxymethane-induced foci of aberrant crypts in rat colon to identify potential cancer chemopreventive agents . Carcinogenesis . 1994;15:1049–1054
  122. Takayama T , Katsuki S , Takahashi Y , et al.   Aberrant crypt foci of the colon as precursors of adenoma and cancer . N Engl J Med . 1998;339:1277–1284

 Current address for S.G.: British Columbia Cancer Agency, Vancouver, BC, Canada.

PII: S0093-7754(04)00467-1

doi: 10.1053/j.seminoncol.2004.09.038

Seminars in Oncology
Volume 32, Issue 1 , Pages 24-34 , February 2005

Article Tools

* Image Usage & Resolution